Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. (Q40509949)
Jump to navigation
Jump to search
scientific article published on September 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. |
scientific article published on September 2004 |
Statements
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma (English)
Leo I Gordon
Thomas Witzig
Arturo Molina
Myron Czuczman
Christos Emmanouilides
Robin Joyce
Katie Vo
Charles Theuer
Brad Pohlman
Greg Wiseman
Mohamed Darif
Christine White
1 September 2004